Workday Posts Upbeat Q2 Results; Insider Confidence Boosts YS Biopharma
- August 25th, 2023
- 518 views
Workday, Inc. (Nasdaq: WDAY), a prominent enterprise software company, reported second-quarter fiscal 2024 earnings of $1.43 per share, surpassing the consensus EPS estimate of $1.26. The company's quarterly sales reached $1.79 billion, slightly exceeding analysts' projected revenue of $1.77 billion.
Additionally, Workday has revised its fiscal 2024 subscription revenue outlook to a range of $6.570 billion to $6.590 billion, marking an 18% year-over-year growth. Moreover, the company has increased its fiscal 2024 non-GAAP operating margin guidance to 23.5%.
$WDAY was trading at $231.79 in after-hours on Thursday, up $6.92 (+3.08%).
In other news, YS Biopharma Co., Ltd. (Nasdaq: YS) said that its Founder and Chairperson, Mr. Yi Zhang, and its Director and CEO, Dr. Hui Shao have purchased 429,188 and 46,300 of its ordinary shares respectively on the open market. Zhang's shares were acquired at an average price of $1.407, while Shao's shares were purchased at an average price of $1.46.
In pre-market, $YS was trading at $1.17, showing an increase of $0.41 (+54.96%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login